<DOC>
	<DOCNO>NCT03043820</DOCNO>
	<brief_summary>There increase clinical molecular evidence role hormone specifically estrogen receptor schizophrenia . A selective estrogen receptor modulator , raloxifene , stimulate estrogen-like activity brain improve cognition old adult . The present study test extent adjunctive raloxifene treatment improve cognition reduce symptom young middle-age men woman schizophrenia . 154 patient schizophrenia spectrum disorder recruit multicenter twelve-week , randomize , double-blind , placebo-controlled , parallel trial adjunctive 120mg raloxifene treatment addition usual antipsychotic medication . The investigator hypothesize daily treatment raloxifene 120 milligram ( mg ) addition antipsychotic treatment improve cognition , reduce psychotic symptom , increase social personal functioning reduce health care cost , compare placebo .</brief_summary>
	<brief_title>Raloxifene Augmentation Patients With Schizophrenia Spectrum Disorder</brief_title>
	<detailed_description>Rationale : Patients schizophrenia spectrum disorder experience substantial impairment multiple domain everyday life , include ability maintain social relationship , sustain employment , live independently . These problem often persist , even successful treatment psychosis . Currently , consistent evidence exists efficacy intervention reduce cognitive negative symptom , fact factor determine function great extent . Premenopausal woman schizophrenia less psychotic negative symptom , well cognitive social functioning , comparison men old woman . This related protective effect estrogens brain . Administering estrogen positive effect psychotic symptom , exert long-term side effect , especially men . Raloxifene selective estrogen receptor modulator , beneficial side effect profile woman men . It show effective reducing symptom postmenopausal woman schizophrenia . Recently , positive result find premenopausal woman men . It important replicate result independent sample investigate effect raloxifene function . Hypotheses : Daily treatment raloxifene 120 milligram ( mg ) addition antipsychotic treatment improve cognition , reduce psychotic symptom , increase social personal functioning reduce health care cost , compare placebo . Objective : The primary objective trial investigate hypothesize beneficial effect raloxifene compare placebo give twelve week addition antipsychotic medication patient psychotic disorder . The investigator expect low symptom severity measure Positive And Negative Symptom Scale ( PANSS ) / Secondary objective include improvement cognition measure Brief Assessment Cognition Schizophrenia ( BACS ) , reducement negative symptom measure Brief Negative Symptom Scale ( BNSS ) , improvement Personal Social Performance ( use PSP-scale ) , reduction think disorder symptom measure Thought And Language Disorder-scale ( TALD ) , reduction use health care recourses use institute Medical Technology Assessment 's Medical Consumption Questionnaire ( iMTA-MCQ ) , productivity use institute Medical Technology Assessment 's Productivity Cost Questionnaire ( iMTA-PCQ ) , improvement quality life use EuroQol-5 dimension scale ( EQ-5D ) , improvement speed error rate Stroop test , reduction comorbid depression use Beck 's Depression Inventory ( BDI ) , improvement language production various hormonal , inflammatory psychophysiological parameter . Study design : Randomized placebo-controlled multicenter double-blind trial Study population : 154 men woman diagnose schizophrenia , schizoaffective schizophreniform disorder , psychotic disorder otherwise specify ( DSM-IV 295 . * ) Intervention : Patients randomize 1:1 either 120mg raloxifene placebo daily period 12 week . Identical tablet administer . Main study parameters/endpoints : Primary outcome change symptom severity measure PANSS . Secondary outcome change cognition , measure BACS , change negative symptom ( measure BNSS ) , change personal social performance ( measure PSP ) , change severity think disorder ( measure TALD ) , quality life ( measure EQ-5D ) , use healthcare non-healthcare resource , comorbid depression ( measure BDI ) , cognitive control ( measure Stroop Test ) , language production ( measure analyze speech sample ) , hormonal inflammatory biomarkers , psychophysiological parameter basic information processing ( i.e . P300 N100 , measure use electroencephalography ) . Nature extent burden risk associate participation , benefit group relatedness : Use raloxifene associate small risk side effect . The number patient visit limit mainly require time invested physical examination , questionnaire cognitive test session ( around 9 hour total course 9 month ) . Blood drawn three occasion negligible know risk ( e.g . irritation ) . The burden risk acceptable benefit expect considerable .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Estrogen Receptor Modulators</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Selective Estrogen Receptor Modulators</mesh_term>
	<criteria>A DSMIVR diagnosis : 295.x ( schizophrenia , schizophreniform disorder , schizoaffective disorder , psychotic disorder NOS ) Capable understand purpose detail study order provide write informed consent ; On stable dose antipsychotic medication least two week ; For female patient : Female patient sexually active must willing capable use nonestrogenic contraceptive ( intrauterine device , cervical cap , condom diaphragm ) case sexual intercourse complete duration study ; Female patient post coital uterine bleeding must document normal PAP smear pelvic examination precede two year . Preexisting cardiovascular disease ; History thromboembolic event ; History breast cancer ; Familial tendency form blood clot ( familial factor V Leiden ) ; Use vitamin K antagonist ; Use cholestyramine anion exchange resin ; Use levothyroxine thyromimetics ; Hypertriglyceridemia ( triglyceride &gt; 3 time upper limit normal ( ULN ) ) ; Liver function enzyme disorder ( serum bilirubin , alkaline phosphatase ( AF ) , gammaglutamyl transpeptidase ( Î³ GT ) , aspartate aminotransferase ( ASAT ) alanine aminotransferase ( ALAT ) &gt; 3 time ULN measure baseline ) ; Severe kidney failure ( eGFR &lt; 30 ml/min measure baseline ) ; Use form estrogen , progestin androgen hormonal therapy , antiandrogen include tibolone use phytoestrogen supplement powder tablet past three month . For female patient : Abnormality observe physical breast examination ; Pregnancy breast feeding ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>raloxifene</keyword>
	<keyword>selective estrogen receptor modulator ( SERM )</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>psychosis</keyword>
	<keyword>cognition</keyword>
	<keyword>negative symptom</keyword>
</DOC>